TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4

• Published in: Journal of experimental & clinical cancer research 2019-03, Vol.38 (1), p.137-137, Article 137
• Main Authors: Wei, Chuan-Yuan, Wang, Lu, Zhu, Meng-Xuan, Deng, Xin-Yi, Wang, Dao-He, Zhang, Si-Min, Ying, Jiang-Hui, Yuan, Xin, Wang, Qiang, Xuan, Tian-Fan, He, An-Qi, Qi, Fa-Zhi, Gu, Jian-Ying
• Format: Article
• Language: English
• Subjects: AKT/mTOR pathway; Animal experimentation; Animals; Bone cancer; Carrier Proteins - genetics; Carrier Proteins - metabolism; Cell cycle; Cell growth; Cell Line, Tumor; Cell Movement; Comparative analysis; Development and progression; Disease; Disease Progression; EMT; Enzymes; Female; Gene Expression Regulation, Neoplastic; Health aspects; Humans; Hypoxia; Liver cancer; Male; Mass spectrometry; Melanoma; Melanoma - genetics; Melanoma - metabolism; Melanoma - pathology; Metastasis; Mice; MicroRNAs; MicroRNAs - genetics; Neoplasm Staging; Neoplasm Transplantation; Prognosis; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Signal Transduction; TLR4; Toll-Like Receptor 4 - genetics; Toll-Like Receptor 4 - metabolism; TOR Serine-Threonine Kinases - metabolism; TRIM44; Up-Regulation
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-019-1138-7

There is growing evidence that tripartite motif-containing protein 44 (TRIM44) plays crucial role in tumor development. However, the underlying mechanism of this deubiquitinating enzyme remains unclear. Large clinical samples were used to detect TRIM44 expression and its associations with clinicopathological features and prognosis. Gain- and loss-of-function experiments in cell lines and mouse xenograft models were performed to elucidate the function and underlying mechanisms of TRIM44 induced tumor progression. Co-immunoprecipitation (Co-IP) assays and mass spectrometric analyses were applied to verify the interacting proteins of TRIM44. We found that TRIM44 was commonly amplified in melanoma tissues compared with paratumoral tissues. TRIM44 expression also positively correlated with more aggressive clinicopathological features, such as Breslow depth (p = 0.025), distant metastasis (p = 0.012), and TNM stage (p = 0.002). Importantly, we found that TRIM44 was an independent indicator of prognosis for melanoma patients. Functionally, overexpression of TRIM44 facilitated cell invasion, migration, apoptosis resistance and proliferation in vitro, and promoted lung metastasis and tumorigenic ability in vivo. Importantly, high level of TRIM44 induced melanoma cell epithelial-mesenchymal transition (EMT), which is one of the most important mechanisms for the promotion of tumor metastasis. Mechanistically, high levels of TRIM44 increased the levels of p-AKT (T308) and p-mTOR (S2448), and a specific AKT inhibitor inhibited TRIM44-induced tumor progression. Co-IP assays and mass spectrometric analyses indicated that TRIM44 overexpression induces cell EMT through activating AKT/mTOR pathway via directly binding and stabilizing TOLL-like receptor 4 (TLR4), and TLR4 interference impeded TRIM44 induced tumor progression. Moreover, we demonstrated that TRIM44 is the target of miR-26b-5p, which is significantly downregulated in melanoma tissues and may be responsible for the overexpression of TRIM44. TRIM44, regulated by miR-26b-5p, promotes melanoma progression by stabilizing TLR4, which then activates the AKT/mTOR pathway. TRIM44 shows promise as a prognostic predictor and a therapeutic target for melanoma patients.